RBC Capital Cuts PT on Nuvation Bio (NUVB) in Q2 Preview
RBC Capital Cuts PT on Nuvation Bio (NUVB) in Q2 Preview.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Nuvation Bio Inc. (NYSE: NUVB ) is one of the best small cap stocks to buy with the highest upside potential . RBC Capital lowered the price target on Nuvation Bio Inc. (NYSE:NUVB) to $19 from $20 on July 7 and reaffirmed an Outperform rating on the shares. The rating update came as part of a broader research note previewing fiscal Q2 earnings in Biotech, with the firm telling investors in the research note that the biotech sector has picked up considerable momentum, with a near-unprecedented two-week move in June relative to the S&P.
This was driven by strong data expanding innovative spaces and perceptions around improving FDA flexibility/stability. The firm further added that with outlooks more concretely definable than other high-volatility spaces, it believes capital could continue to flow in. It also stated that fiscal Q2 earnings are shaping up to be seasonally strong, and with multiple opportunities for beats and the M&A resurgence likely to continue, there is little that would materially derail things.
Nuvation Bio (NYSE:NUVB) is a biopharmaceutical company that develops novel therapeutic and differentiated candidates to tackle the gaps in oncology. The company's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates.
While we acknowledge the potential of NUVB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow .
Sinergia Empresarial continuará el seguimiento de esta información sobre rBC Capital Cuts PT on Nuvation Bio (NUVB) in Q2 Preview y ampliará la cobertura conforme se confirmen nuevos elementos relevantes para el ecosistema empresarial.
